Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06010667

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Sponsor: Hebei Medical University Fourth Hospital

View on ClinicalTrials.gov

Summary

The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

OBSERVATIONAL

Enrollment

60

Start Date

2023-09-01

Completion Date

2026-08-01

Last Updated

2023-08-24

Healthy Volunteers

No

Interventions

DRUG

Envafolimab

With or without Envafolimab

Locations (1)

Hebei

Shijiazhuang, Hebei, China